Associated Papers
Identification of DPYD variants and estimation of uracil and dihydrouracil in a healthy Indian population.
Sivamani P et al.
Personalized Medicine, 2023
Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer.
Almashagbah NA et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2022
Genetic Variations of the DPYD Gene and Its Relationship with Ancestry Proportions in Different Ecuadorian Trihybrid Populations.
Farinango C et al.
Journal of Personalized Medicine, 2022
35743735 (PubMed )
Supplement: jpm-12-00950-s001.zip › jpm-1734647-supplementary.xlsx › Table_S2
Development of a Pharmacogenetic Lab-on-Chip Assay Based on the In-Check Technology to Screen for Genetic Variations Associated to Adverse Drug Reactions to Common Chemotherapeutic Agents.
Iemmolo R et al.
Biosensors, 2020
Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.
Shrestha S et al.
Clinical Pharmacology and Therapeutics, 2018
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2018
Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.
Ng D et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2017
27537706 (PubMed )
Supplement: NIHMS802548-supplement-Table_S4.pdf
ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
Li Z et al.
Oncotarget, 2016
27487151 (PubMed )
Supplement: oncotarget-07-55449-s001.pdf
Select a paper to view details